Sartorius Aktiengesellschaft (0NIQ.L)
EUR 159.0
(1.02%)
EUR 159.0
(1.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 811.2 Million EUR | -45.01% |
| 2022 | 1.53 Billion EUR | 24.49% |
| 2021 | 945.12 Million EUR | 67.48% |
| 2020 | 662.12 Million EUR | 42.13% |
| 2019 | 463.53 Million EUR | 21.09% |
| 2018 | 409.17 Million EUR | 27.89% |
| 2017 | 326.22 Million EUR | 11.12% |
| 2016 | 297.2 Million EUR | 10.15% |
| 2015 | 252.59 Million EUR | 51.55% |
| 2014 | 173.3 Million EUR | 12.08% |
| 2013 | 154.62 Million EUR | -1.15% |
| 2012 | 146.25 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 239.5 Million EUR | 1.2% |
| 2024 Q2 | 206.1 Million EUR | -4.93% |
| 2024 Q3 | 181.2 Million EUR | -19.0% |
| 2023 FY | - EUR | -39.88% |
| 2023 Q4 | 156.2 Million EUR | -37.64% |
| 2023 Q2 | 293.4 Million EUR | -4.18% |
| 2023 Q1 | 306.2 Million EUR | -27.6% |
| 2023 Q3 | 250.5 Million EUR | -14.62% |
| 2022 Q2 | 362.9 Million EUR | -1.06% |
| 2022 Q1 | 366.8 Million EUR | 18.48% |
| 2022 FY | - EUR | 24.49% |
| 2022 Q3 | 384.5 Million EUR | 5.95% |
| 2022 Q4 | 422.9 Million EUR | 9.99% |
| 2021 Q2 | 298.7 Million EUR | 15.6% |
| 2021 Q4 | 309.6 Million EUR | -8.86% |
| 2021 FY | - EUR | 67.48% |
| 2021 Q1 | 258.39 Million EUR | 33.41% |
| 2021 Q3 | 339.7 Million EUR | 13.73% |
| 2020 Q1 | 138.7 Million EUR | 6.41% |
| 2020 Q2 | 141.4 Million EUR | 1.95% |
| 2020 Q3 | 187.2 Million EUR | 32.39% |
| 2020 Q4 | 193.68 Million EUR | 3.46% |
| 2020 FY | - EUR | 42.13% |
| 2019 Q3 | 115.9 Million EUR | -2.03% |
| 2019 Q1 | 114.1 Million EUR | 3.57% |
| 2019 FY | - EUR | 21.09% |
| 2019 Q4 | 130.35 Million EUR | 12.47% |
| 2019 Q2 | 118.3 Million EUR | 3.68% |
| 2018 Q2 | 94.2 Million EUR | 6.2% |
| 2018 FY | - EUR | 27.89% |
| 2018 Q4 | 110.16 Million EUR | 10.61% |
| 2018 Q1 | 88.7 Million EUR | -6.44% |
| 2018 Q3 | 99.6 Million EUR | 5.73% |
| 2017 FY | - EUR | 11.12% |
| 2017 Q1 | 84.5 Million EUR | -4.41% |
| 2017 Q2 | 79.8 Million EUR | -5.56% |
| 2017 Q3 | 73.4 Million EUR | -8.02% |
| 2017 Q4 | 94.8 Million EUR | 29.16% |
| 2016 Q2 | 77.3 Million EUR | 6.92% |
| 2016 FY | - EUR | 10.15% |
| 2016 Q4 | 88.39 Million EUR | 11.75% |
| 2016 Q3 | 79.1 Million EUR | 2.33% |
| 2016 Q1 | 72.3 Million EUR | 5.64% |
| 2015 Q3 | 70.1 Million EUR | 13.61% |
| 2015 FY | - EUR | 51.55% |
| 2015 Q2 | 61.7 Million EUR | 7.3% |
| 2015 Q1 | 57.5 Million EUR | 44.44% |
| 2015 Q4 | 68.44 Million EUR | -2.36% |
| 2014 Q2 | 46 Million EUR | 17.65% |
| 2014 Q1 | 39.1 Million EUR | 37.06% |
| 2014 Q3 | 45.6 Million EUR | -0.87% |
| 2014 Q4 | 39.8 Million EUR | -12.7% |
| 2014 FY | - EUR | 12.08% |
| 2013 Q2 | 43.1 Million EUR | 9.95% |
| 2013 Q1 | 39.2 Million EUR | 3.37% |
| 2013 Q3 | 39.7 Million EUR | -7.89% |
| 2013 Q4 | 28.52 Million EUR | -28.14% |
| 2013 FY | - EUR | -1.15% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | 37.92 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cegedim SA | 95.25 Million EUR | -751.645% |
| Guerbet SA | 90.09 Million EUR | -800.393% |
| Nexus AG | 53.43 Million EUR | -1418.22% |
| Bastide Le Confort Médical SA | 110.32 Million EUR | -635.289% |
| Revenio Group Oyj | 30.09 Million EUR | -2595.912% |
| Drägerwerk AG & Co. KGaA | 318.33 Million EUR | -154.827% |
| LNA Santé SA | 144.63 Million EUR | -460.86% |
| Siemens Healthineers AG | 4.22 Billion EUR | 80.8% |
| Medios AG | 52.81 Million EUR | -1435.898% |
| Equasens Société anonyme | 71.29 Million EUR | -1037.744% |
| Stratec SE | 39.82 Million EUR | -1937.116% |